Biomx Inc Stock Price, News & Analysis

BiomX Inc. (PHGE), a clinical-stage microbiome company, announced a conference call on November 9, 2022, at 8:00 a.m. ET to discuss its third quarter 2022 financial results and provide business updates. The conference will be accessible via phone or through a live audio webcast on the company's website. BiomX focuses on developing natural and engineered phage therapies aimed at treating chronic diseases by targeting specific pathogenic bacteria. More details can be found on their website.

BiomX Inc. (NYSE American: PHGE), a clinical-stage microbiome company, announced that CEO Jonathan Solomon will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022, at 7:00 AM EST. The conference runs from September 12-14, 2022. Presentations will be available on-demand, and the webcasts can be accessed via the BiomX Investors section post-event. The company focuses on developing phage therapies targeting pathogenic bacteria to treat chronic diseases.

BiomX (PHGE) updates on its Phase 1b/2a trial for BX004, targeting lung infections in cystic fibrosis (CF), with results expected by Q3 2022. The company entered a collaboration with Boehringer Ingelheim to discover microbiome markers for inflammatory bowel disease. BiomX published significant research articles, including one in Cell, and has extended its cash runway through mid-2024 with a current cash position of $46.7 million. Despite a net loss of $7.5 million in Q2 2022, the company is focused on key milestones to enhance shareholder value.

BiomX Inc. (NYSE American: PHGE) announced a conference call on August 10, 2022, at 8:00 a.m. EDT to discuss its second-quarter financial results and business updates. The company specializes in developing natural and engineered phage therapies targeting pathogenic bacteria for chronic disease treatment. Investors can participate by calling a designated number or accessing the webcast through the company's website.

BiomX Inc. (PHGE) announced the publication of a significant study confirming the efficacy of its phage therapy candidate BX003 targeting Klebsiella pneumoniae in inflammatory bowel disease (IBD). Conducted with leading academic institutions, the research demonstrated safety and tolerability in a Phase 1a trial, as well as effective suppression of pathogenic bacteria in colitis-prone mice. The findings enhance the scientific basis for BX003’s potential in treating IBD, emphasizing collaboration in advancing treatment for challenging diseases.

BiomX Inc. (NYSE American: PHGE) announced its decision to voluntarily delist from the Tel Aviv Stock Exchange (TASE), effective October 6, 2022. This move is based on a review of trading volumes and the costs associated with maintaining multiple exchange listings. BiomX believes that consolidating its listing to the NYSE American is in the best interest of shareholders. Following the delisting, all shares on the TASE will transition to continue trading on the NYSE American.

BiomX has announced a collaboration with Boehringer Ingelheim to identify biomarkers for inflammatory bowel disease (IBD) using its XMarker discovery platform. This collaboration follows their first in September 2020, demonstrating ongoing partnership efforts in IBD research. BiomX aims to leverage its technology to help delineate patient segments based on their microbiome, potentially enhancing treatment specificity. The agreement includes research payments and an option for Boehringer Ingelheim to obtain exclusive rights to any discovered biomarkers, while BiomX retains rights for companion diagnostics.

BiomX (AMEX: PHGE) announced the dosing of its first two patients in a Phase 1b/2a study evaluating BX004 for treating chronic respiratory infections in cystic fibrosis patients. This clinical milestone is aimed at assessing BX004's safety and clinical activity against antibiotic-resistant P. aeruginosa. Results from Part 1 are expected in Q3 2022, followed by Part 2, which involves a larger cohort. The company received a $5 million award from the Cystic Fibrosis Foundation to support its development efforts.

BiomX (AMEX: PHGE) announces a corporate restructuring plan to enhance capital resources, cutting headcount by 50%. The cash runway is extended to at least mid-2024, with $55.7 million in cash and a $15 million debt facility reported as of March 31, 2022. The Cystic Fibrosis (CF) program is progressing, with initial results from the Phase 1b/2a study of BX004 expected in Q3 2022. However, the Atopic Dermatitis program will face delays due to the restructuring.